These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34924209)

  • 1. Microbial protein cell factories fight back?
    ;
    Trends Biotechnol; 2022 May; 40(5):576-590. PubMed ID: 34924209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotherapeutic Products, Cellular Factories, and Multiomics Integration in Metabolic Engineering.
    Hoang Anh N; Min JE; Kim SJ; Phuoc Long N
    OMICS; 2020 Nov; 24(11):621-633. PubMed ID: 33064624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current trends in biopharmaceuticals production in Escherichia coli.
    McElwain L; Phair K; Kealey C; Brady D
    Biotechnol Lett; 2022 Aug; 44(8):917-931. PubMed ID: 35796852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.
    Dumont J; Euwart D; Mei B; Estes S; Kshirsagar R
    Crit Rev Biotechnol; 2016 Dec; 36(6):1110-1122. PubMed ID: 26383226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic engineering approaches to improve posttranslational modification of biopharmaceuticals in different production platforms.
    Amann T; Schmieder V; Faustrup Kildegaard H; Borth N; Andersen MR
    Biotechnol Bioeng; 2019 Oct; 116(10):2778-2796. PubMed ID: 31237682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutical discovery and production in yeast.
    Meehl MA; Stadheim TA
    Curr Opin Biotechnol; 2014 Dec; 30():120-7. PubMed ID: 25014890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yeast synthetic biology for the production of recombinant therapeutic proteins.
    Kim H; Yoo SJ; Kang HA
    FEMS Yeast Res; 2015 Feb; 15(1):1-16. PubMed ID: 25130199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems biotechnology of mammalian cell factories.
    O'Callaghan PM; James DC
    Brief Funct Genomic Proteomic; 2008 Mar; 7(2):95-110. PubMed ID: 18326543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industrial systems biology and its impact on synthetic biology of yeast cell factories.
    Fletcher E; Krivoruchko A; Nielsen J
    Biotechnol Bioeng; 2016 Jun; 113(6):1164-70. PubMed ID: 26524089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in technology supporting biopharmaceutical production from mammalian cells.
    Butler M; Meneses-Acosta A
    Appl Microbiol Biotechnol; 2012 Nov; 96(4):885-94. PubMed ID: 23053101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of 'Omics technology to rationally improve industrial mammalian cell line performance.
    Lewis AM; Abu-Absi NR; Borys MC; Li ZJ
    Biotechnol Bioeng; 2016 Jan; 113(1):26-38. PubMed ID: 26059229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yeast synthetic biology for designed cell factories producing secretory recombinant proteins.
    Thak EJ; Yoo SJ; Moon HY; Kang HA
    FEMS Yeast Res; 2020 Mar; 20(2):. PubMed ID: 32009173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology, bionanotechnology and microbial cell factories.
    Villaverde A
    Microb Cell Fact; 2010 Jul; 9():53. PubMed ID: 20602780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation and identification of functional post-translational modification sites associated with drug binding and protein-protein interactions.
    Su MG; Weng JT; Hsu JB; Huang KY; Chi YH; Lee TY
    BMC Syst Biol; 2017 Dec; 11(Suppl 7):132. PubMed ID: 29322920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-translational modifications in the context of therapeutic proteins.
    Walsh G; Jefferis R
    Nat Biotechnol; 2006 Oct; 24(10):1241-52. PubMed ID: 17033665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.
    Corchero JL; Gasser B; Resina D; Smith W; Parrilli E; Vázquez F; Abasolo I; Giuliani M; Jäntti J; Ferrer P; Saloheimo M; Mattanovich D; Schwartz S; Tutino ML; Villaverde A
    Biotechnol Adv; 2013; 31(2):140-53. PubMed ID: 22985698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding biopharmaceutical production at single nucleotide resolution using ribosome footprint profiling.
    Tzani I; Monger C; Kelly P; Barron N; Kelly RM; Clarke C
    Curr Opin Biotechnol; 2018 Oct; 53():182-190. PubMed ID: 29471208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From omics to Cellular mechanisms in mammalian cell factory development.
    Samoudi M; Masson HO; Kuo CC; Robinson CM; Lewis NE
    Curr Opin Chem Eng; 2021 Jun; 32():. PubMed ID: 37475722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Genome Editing Tool for the Production of Industrial Biopharmaceuticals.
    Khan AH; Tye GJ; Noordin R
    Mol Biotechnol; 2020 Sep; 62(9):401-411. PubMed ID: 32749657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging CHO systems biology era: harnessing the 'omics revolution for biotechnology.
    Kildegaard HF; Baycin-Hizal D; Lewis NE; Betenbaugh MJ
    Curr Opin Biotechnol; 2013 Dec; 24(6):1102-7. PubMed ID: 23523260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.